Lancet Oncology APC and Open Access: High IF, High Price, and Limited Institutional Coverage

This is the critical detail for Lancet Oncology's APC. All Lancet family journals are excluded from most Elsevier Read & Publish agreements.

The reason: Lancet titles are published by Elsevier, but they operate with significant editorial independence and a separate business model. When Elsevier negotiates Read & Publish deals with universities and consortia, Lancet journals (along with Cell Press titles and many society journals) are carved out.

Some individual institutions have negotiated specific Lancet coverage, but these are exceptions. The vast majority of researchers who publish OA in Lancet Oncology pay from grant funds or departmental budgets.

This is a recurring frustration for researchers who see Elsevier's name on the journal and assume their institution's Elsevier agreement applies. It doesn't. Always check with your library specifically about Lancet coverage.

The Lancet publishes multiple journals relevant to cancer researchers:

If your cancer paper has implications beyond oncology, the flagship Lancet is even more prestigious but harder to get into and more expensive for OA. eBioMedicine is a cheaper OA alternative within the Lancet ecosystem, though its scope is broader and its IF is lower.

Lancet Oncology doesn't have a direct gold OA companion journal in the way that Blood has Blood Advances or Hepatology has Hepatology Communications. If your paper doesn't reach Lancet Oncology's bar, the Lancet family doesn't offer a natural step-down within oncology specifically. You'd need to look at journals from other publishers.

Elsevier manages Lancet Oncology's waiver program:

Automatic geographical waivers:

• Corresponding authors in Research4Life Group A countries receive a full APC waiver.
• Authors in Group B countries receive a 50% discount.

Case-by-case hardship waivers:

• Available upon request at acceptance.
• Elsevier states that editorial decisions are independent of payment.
• Approval isn't guaranteed.

No society membership discounts:

• There's no ESMO or ASCO discount for Lancet Oncology. The fee is the same regardless of society membership.

Institutional agreements:

• Very rare for Lancet titles specifically. A handful of institutions have negotiated direct coverage, but these are exceptions.

For well-funded oncology researchers at major cancer centers, the expectation is that NCI, ERC, or foundation grants cover the APC. The waiver system is designed for researchers who genuinely lack access to publication funds.

For NIH/NCI-funded cancer research, the cheapest compliant route is the subscription track plus PMC deposit after the embargo. This costs nothing and satisfies federal mandates. Most NCI-funded researchers use this path.

Plan S compliance costs real money at Lancet Oncology. CC BY licensing puts you at ~$6,300-$6,500, and your institution's Elsevier deal won't cover it. European researchers on ERC or national council grants should budget for this explicitly.

The Wellcome Trust and HHMI typically cover APCs directly through their OA funding programs. If you have Wellcome or HHMI funding, the APC is usually not a financial burden, but you need to arrange payment before the invoice arrives.

Understanding what Lancet Oncology publishes helps you assess whether the APC is a worthwhile investment:

• Phase III clinical trials in solid tumors and hematologic malignancies
• Practice-changing Phase II trials with strong endpoints
• Large meta-analyses and pooled analyses of clinical trial data
• Health policy and cancer care delivery research
• Cancer epidemiology with global public health implications
• Personal Views and Comments (invited, no APC)

The journal has a distinctly European editorial voice. European cooperative group trials are heavily represented. EORTC, ESMO-sponsored studies, and UK-based trials are core content. North American researchers publish there too, but the editorial gravity tilts toward Europe.

Lancet Oncology's desk-rejection rate exceeds 80%. The journal receives thousands of submissions annually and publishes roughly 200-250 original research articles. Competition is fierce, and the editors prioritize studies that will change clinical practice globally.

• License choice significantly affects price. CC BY costs ~$1,000-$1,300 more than CC BY-NC-ND. If your funder doesn't specifically require CC BY, the cheaper license saves real money.
• No institutional safety net for most researchers. Budget the full APC in your grant application. Assuming Elsevier coverage will appear is a mistake.
• Embargo period for subscription track. Lancet journals typically have a 12-month embargo before the accepted manuscript can be freely shared.
• Strict formatting and word limits. Lancet Oncology enforces tight word counts and structured formats. Exceeding limits leads to desk rejection, not just a request to shorten.
• Extended data and appendix expectations. Large clinical trials are expected to submit extensive supplementary data, protocol documents, and statistical analysis plans.

For oncology researchers choosing where to submit, cost should be one factor among many:

1. Cost is your priority? JCO is free. It's the same tier of prestige. Submit there unless your paper is a better editorial fit for Lancet Oncology.
2. European cooperative group trial? Lancet Oncology is the natural home. Budget ~$5,200-$6,500 for OA from your grant.
3. Plan S funder? Budget ~$6,300-$6,500 for CC BY. Your Elsevier deal won't help.
4. NIH-funded? Publish via subscription (free). Deposit in PMC after the embargo.
5. Didn't get into Lancet Oncology? Annals of Oncology (IF ~35) and JAMA Oncology (IF ~29) are strong alternatives at lower prices.

Lancet Oncology's prestige is real. An IF of ~42 places it among the top five oncology journals worldwide, and its readership includes decision-makers in European oncology policy. For the right paper, the APC is justified. For papers that could go equally well to JCO, the cost difference is hard to ignore.

Before submitting, make sure your trial design, reporting standards (CONSORT, STROBE), and clinical framing meet Lancet Oncology's expectations. Run a free readiness scan to catch issues before they trigger a desk rejection at this level.

For current APC amounts and author guidelines, visit the Lancet Oncology author information page.